sem cell lines harboring kmt2a Search Results


sem cell lines harboring kmt2a  (DSMZ)
95
DSMZ sem cell lines harboring kmt2a
Sem Cell Lines Harboring Kmt2a, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sem+cell+lines+harboring+kmt2a/SEM/pm38029383-53-2-7
Average 95 stars, based on 1 article reviews
sem cell lines harboring kmt2a - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
human kmt2a r  (DSMZ)
95
DSMZ human kmt2a r
A) Smarca4 expressions in different murine hardy B fractions – ‘CLP’: Common lymphoid progenitor, ‘Fr. A’: Pre-Pro B, ‘Fr. B’: Early Pro B, ‘Fr. C’: Late Pro B / Large Pre-B, ‘Fr. D’: Small Pre-B, ‘Fr. E’: Immature B, and ‘Fr. F’: Mature B cells (GSE38463). B) Expression of Smarca4 in different murine B developmental stages and lymphoma models (GSE26408). C) SMARCA4 expressions in B-ALL populations compared to T-ALL, CD19+, and CD34+ populations (GSE33315). D) SMARCA4 expressions in different subtypes of B-ALL populations (GSE11877). E) Western blot analysis of BRG1, BRM, and β-actin in four <t>KMT2A</t> -R (SEM, <t>HB11;19,</t> <t>RS4;11,</t> <t>KOPN8)</t> and two Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines. F) Mutational frequencies of different oncogenes in B-ALL patient populations from the COG study P9906 (GSE11877). G) Dependency analysis of SMARCA4 via the Cancer Dependency MAP website. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by One-way Anova Dunnett’s multiple comparison test.
Human Kmt2a R, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sem+cell+lines+harboring+kmt2a/RS4%3B11/bio_rxiv__2025__07__08__661805-119-0-24
Average 95 stars, based on 1 article reviews
human kmt2a r - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


A) Smarca4 expressions in different murine hardy B fractions – ‘CLP’: Common lymphoid progenitor, ‘Fr. A’: Pre-Pro B, ‘Fr. B’: Early Pro B, ‘Fr. C’: Late Pro B / Large Pre-B, ‘Fr. D’: Small Pre-B, ‘Fr. E’: Immature B, and ‘Fr. F’: Mature B cells (GSE38463). B) Expression of Smarca4 in different murine B developmental stages and lymphoma models (GSE26408). C) SMARCA4 expressions in B-ALL populations compared to T-ALL, CD19+, and CD34+ populations (GSE33315). D) SMARCA4 expressions in different subtypes of B-ALL populations (GSE11877). E) Western blot analysis of BRG1, BRM, and β-actin in four KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and two Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines. F) Mutational frequencies of different oncogenes in B-ALL patient populations from the COG study P9906 (GSE11877). G) Dependency analysis of SMARCA4 via the Cancer Dependency MAP website. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by One-way Anova Dunnett’s multiple comparison test.

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: A) Smarca4 expressions in different murine hardy B fractions – ‘CLP’: Common lymphoid progenitor, ‘Fr. A’: Pre-Pro B, ‘Fr. B’: Early Pro B, ‘Fr. C’: Late Pro B / Large Pre-B, ‘Fr. D’: Small Pre-B, ‘Fr. E’: Immature B, and ‘Fr. F’: Mature B cells (GSE38463). B) Expression of Smarca4 in different murine B developmental stages and lymphoma models (GSE26408). C) SMARCA4 expressions in B-ALL populations compared to T-ALL, CD19+, and CD34+ populations (GSE33315). D) SMARCA4 expressions in different subtypes of B-ALL populations (GSE11877). E) Western blot analysis of BRG1, BRM, and β-actin in four KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and two Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines. F) Mutational frequencies of different oncogenes in B-ALL patient populations from the COG study P9906 (GSE11877). G) Dependency analysis of SMARCA4 via the Cancer Dependency MAP website. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by One-way Anova Dunnett’s multiple comparison test.

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Expressing, Western Blot, Comparison

Kaplan-Meier analysis of the overall survival of all B-ALL (A) , Ph-like B-ALL (B) , and KMT2A -R B-ALL (C) patients from the COG study P9906 with high vs low SMARCA4 mRNA expression (GSE11877). D) Ph-like (red; MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (blue; HB11;19 and KOPN8) were treated with increasing concentrations of BRM014 (left) or FHD-286 (right). Viability/cell proliferation was determined via an XTT assay after 72 hours. E) GSEA enrichment plots of Ph-like (MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. “NES” refers to the Normalized enrichment score (GSE297161). F) RT-PCR was performed to determine the gene expression levels of the indicated genes in Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. ACTB (Beta Actin) was used as a reference gene to calculate expression levels. Significance was calculated via a log-rank test in Prism (A-C) . Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Sidak’s multiple comparison test (F) or two-sided Log-rank (Mantel-Cox) test (A-C) .

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: Kaplan-Meier analysis of the overall survival of all B-ALL (A) , Ph-like B-ALL (B) , and KMT2A -R B-ALL (C) patients from the COG study P9906 with high vs low SMARCA4 mRNA expression (GSE11877). D) Ph-like (red; MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (blue; HB11;19 and KOPN8) were treated with increasing concentrations of BRM014 (left) or FHD-286 (right). Viability/cell proliferation was determined via an XTT assay after 72 hours. E) GSEA enrichment plots of Ph-like (MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. “NES” refers to the Normalized enrichment score (GSE297161). F) RT-PCR was performed to determine the gene expression levels of the indicated genes in Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. ACTB (Beta Actin) was used as a reference gene to calculate expression levels. Significance was calculated via a log-rank test in Prism (A-C) . Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Sidak’s multiple comparison test (F) or two-sided Log-rank (Mantel-Cox) test (A-C) .

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Expressing, XTT Assay, Control, Reverse Transcription Polymerase Chain Reaction, Gene Expression, Comparison

A) Cell cycle analysis of the Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after treatment with 100 nM BRM014 or FHD-286 for 72h. On the left are representative examples of the flow cytometric analysis (n=3), and on the right is the summary of all three experiments. B) Cell viability and apoptosis were tested in control- and BRG1/BRM inhibitor-treated (BRM014 or FHD-286; 100 nM; 72h) Ph-like (MHH-CALL4) and KMT2A -R (SEM and RS4;11) B-ALL cell lines. On the left are representative examples of the flow cytometric analysis (n=3) and on the right is the summary of all three experiments. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Dunnett’s multiple comparison test.

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: A) Cell cycle analysis of the Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after treatment with 100 nM BRM014 or FHD-286 for 72h. On the left are representative examples of the flow cytometric analysis (n=3), and on the right is the summary of all three experiments. B) Cell viability and apoptosis were tested in control- and BRG1/BRM inhibitor-treated (BRM014 or FHD-286; 100 nM; 72h) Ph-like (MHH-CALL4) and KMT2A -R (SEM and RS4;11) B-ALL cell lines. On the left are representative examples of the flow cytometric analysis (n=3) and on the right is the summary of all three experiments. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Dunnett’s multiple comparison test.

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Cell Cycle Assay, Control, Comparison